Item 2.02. Results of Operations and Financial Condition.

The information contained in Item 7.01 below and Exhibit 99.1 attached hereto, to the extent it relates to Jounce Therapeutics, Inc.'s (the "Company") cash position as of December 31, 2020, is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The Company prepared the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K (the "Corporate Presentation"), which will be presented by the Company's management during investor meetings beginning on January 11, 2021. Information from this Corporate Presentation may also be used by the management of the Company in future meetings regarding the Company. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

The information in Item 2.02 and Item 7.01 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits
Exhibit No.             Description
  99.1                    Corporate Presentation of Jounce Therapeutics, Inc., dated January 2021
104                     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses